Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X about recent paper by Antonio Calles et al., titled “Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study” published on Journal of Thoracic Oncology.

Authors: Antonio Calles, Alejandro Navarro, Bernard Gaston Doger Speville Uribe, Enric Álvarez Colomé, María de Miguel, Rosa Álvarez, Marta Arregui, Víctor Moreno, Pedro Rocha, Emiliano Calvo, Jorge Ramon-Patino, Elena Corral de la Fuente, Daniel Alcalá-López, Olga Boix, Melissa Fernández-Pinto, Jose Rodríguez-Morató, Ramón Palmero, Ernest Nadal, Maria Jove, Enriqueta Felip.

Estela Rodriguez: Great work by Antonio Calles et al. on LUPER Ph1/2 study

“Great work by Tony Calles and Spanish investigators on LUPER Ph1/2 Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC).
N=28, no prior.
ORR 46%.
Better OS on platinum-sensitive -15.7 vs 7 months.
Small study, not applicable to patients getting 1L chemoIO but signal of activity to investigate further.”